208 related articles for article (PubMed ID: 31659379)
1. [Studies on radiotherapy of head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Ott S; Wiegel T; Hoffmann TK; Petersen C; Tribius S; Laban S
HNO; 2019 Dec; 67(12):918-924. PubMed ID: 31659379
[TBL] [Abstract][Full Text] [Related]
2. [Radiotherapeutic studies of head and neck cancer-highlights of the 2018 ASCO Annual Meeting].
Ott S; Wiegel T; Laban S; Hoffmann TK; Petersen C; Tribius S
HNO; 2018 Dec; 66(12):901-906. PubMed ID: 30421001
[TBL] [Abstract][Full Text] [Related]
3. [Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer].
Hecht M; von der Grün J; Semrau S; Müller S; Weissmann T; Gaipl US; Iro H; Fietkau R; Gostian AO
HNO; 2022 Apr; 70(4):258-264. PubMed ID: 35294576
[TBL] [Abstract][Full Text] [Related]
4. [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Chilimoniuk M; Olszewska E; Maksimowicz T
Pol Merkur Lekarski; 2010 Dec; 29(174):357-60. PubMed ID: 21298984
[TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
Quon H; Vapiwala N; Forastiere A; Kennedy EB; Adelstein DJ; Boykin H; Califano JA; Holsinger FC; Nussenbaum B; Rosenthal DI; Siu LL; Waldron JN
J Clin Oncol; 2017 Dec; 35(36):4078-4090. PubMed ID: 29064744
[TBL] [Abstract][Full Text] [Related]
6. [Update on HPV-associated head and neck cancer-highlights from the 2019 ASCO Annual Meeting].
Tribius S; Würdemann N; Laban S; Hoffmann TK; Sharma SJ; Klussmann JP
HNO; 2019 Dec; 67(12):912-917. PubMed ID: 31701169
[TBL] [Abstract][Full Text] [Related]
7. [Update on HPV-associated head and neck cancer-highlights of the 2018 ASCO Annual Meeting].
Tribius S; Würdemann N; Laban S; Sharma SJ; Wagner S; Hoffmann TK; Wittekindt C; Klussmann JP
HNO; 2018 Dec; 66(12):888-895. PubMed ID: 30350217
[TBL] [Abstract][Full Text] [Related]
8. [Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].
Gliese A; Busch CJ; Knecht R
HNO; 2014 Nov; 62(11):781-6. PubMed ID: 25274201
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler P; Hoffmann TK; Laban S
HNO; 2019 Dec; 67(12):905-911. PubMed ID: 31612261
[TBL] [Abstract][Full Text] [Related]
10. [Highlights of the ASCO and ESMO annual meetings 2022: radiotherapy of head and neck cancer].
Schnellhardt S; Linxweiler M; Gostian AO; Hecht M
HNO; 2023 Jul; 71(7):446-452. PubMed ID: 37296331
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers].
Laban S; Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler PJ; Hoffmann TK
HNO; 2018 Dec; 66(12):880-887. PubMed ID: 30402813
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy and targeted therapy of head and neck squamous cell carcinomas at the 2021 ASCO meeting].
Blaurock M; Busch CJ
HNO; 2022 Apr; 70(4):265-270. PubMed ID: 35257190
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
15. [Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Gliese A; Busch CJ; Knecht R
HNO; 2016 Oct; 64(10):717-22. PubMed ID: 27624903
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of head and neck cancer : Highlights of the ASCO and ESMO annual meetings 2021].
Theodoraki MN; Laban S; Hoffmann TK
HNO; 2022 Apr; 70(4):271-277. PubMed ID: 35037989
[TBL] [Abstract][Full Text] [Related]
17. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
18. Overview of combined modality therapies for head and neck cancer.
Dimery IW; Hong WK
J Natl Cancer Inst; 1993 Jan; 85(2):95-111. PubMed ID: 8418313
[TBL] [Abstract][Full Text] [Related]
19. [The most important study results concerning nonsurgical primary treatment of locally advanced head and neck cancer: Highlights of the ASCO Meeting 2015].
Gliese A; Busch CJ; Knecht R
HNO; 2015 Sep; 63(9):606-11. PubMed ID: 26303521
[TBL] [Abstract][Full Text] [Related]
20. ASCO highlights podcast: head and neck cancers.
Merlano M
ESMO Open; 2016; 1(5):e000099. PubMed ID: 27843642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
